Earnings ·
AtriCure reports Q3 revenue of $154.5M and raises full-year guidance to $606M-$610M
ATRCAtriCure, Inc.
AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, a 15% increase year over year, driven by growth in U.S. open ablation and pain management sales. The company achieved net income of $4.1 million and adjusted EBITDA of $26.8 million, reflecting improved profitability with gross margins expanding to 77.3%. Management raised full-year 2026 revenue guidance to approximately $606 million to $610 million and projected adjusted EBITDA of $91 million to $94 million. The firm develops medical devices for the treatment of atrial fibrillation, left atrial appendage management, and post-operative pain management.